Both EGFR tyrosine kinase inhibitor, erlotinib, and MEK inhibitor, selumetinib (AZD6244), significantly suppress tumor growth and induce G1 arrest in a CCC xenograft model in a PEA-15 dependent manner, and knockdown of PEA-15 results in selumetinib-resistant cells [86]. This evidence concerns the gene PEA15 and neoplasm.